Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories


AstraZeneca’s Soriot Dismisses Any Pfizer Vaccine ‘Envy’ Amid Buoyant Q2 Results

The UK company has raised its forecasts for 2021 after a better-than-expected Q2, even though Vaxzevria remains a very mixed blessing.

BioPharmaceutical

Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend

Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.

Sales & Earnings Deals Business Strategies

Sanofi’s Dupixent Benefits In Chronic Spontaneous Urticaria Add To Strong Second Quarter

Sanofi’s sales grew strongly in the second quarter, driven by the immunologic Dupixent and its vaccines business, with the company also reporting success in a further potential indication for the product, chronic spontaneous urticaria. The big pharma has raised its EPS guidance for the year.

Sales & Earnings Inflammation Clinical Trials

Scrip Podcast


Recent Tweets from Scrip


 

Infographics

Titans Of Pharma 2021: J&J’s Gorsky Tops Big Pharma Remuneration

INFOGRAPHIC: A snapshot of the compensation packages of CEOs and R&D leaders of the world’s biggest pharmaceutical companies, alongside median employee pay and key company performance metrics.

Leadership Strategy

Pandemic Perspectives: 20-Plus Vaccines In Development As India Tackles COVID-19 Surge

From mRNA to subunit vaccines, Indian companies have 20 COVID-19 vaccine candidates, while three have already been approved. An August nod for Biological E could not just cut down time to immunize the country's population but also allow exports to resume.

India Coronavirus COVID-19

The 2021 Worldwide Pharma And Biotech R&D Scene

INFOGRAPHIC: A snapshot of the industry in key performance indicators surrounding R&D taken in early 2021.

Companies Market Intelligence

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

Dawn Of A New Era? Korean Biopharma M&A Landscape Set For Change

Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.

South Korea M & A

Pandemic Still Weighs On Gilead’s HIV Business, But Signs Of Recovery

HIV PrEP and treatments saw increases in sales, though the US treatment market’s recovery was slower than expected and may need “several” quarters to return to pre-pandemic levels.

Sales & Earnings Coronavirus COVID-19

GSK Exceeds Expectations In Q2, But Still Awaiting Shingrix Bounce Back

While demand for Shingrix is expected to return in the US, the slow process of COVID-19 vaccination in many other countries will delay its uptake.

Commercial Companies

Torrent’s Entry Into Indian Trade Generics Signals Strategy Shift

Faced with a slowdown in the US from a lack of regulatory approvals, Torrent Pharma is looking at alternate growth strategies. Its entry into the trade generics segment in India, joining other pharma majors, is one to be watched as it marks a strategic shift.

Commercial Sales & Earnings

Dr Reddy’s Gears For Sputnik Light In India, Jab For Adolescents

Dr Reddy’s is to press ahead with India filing plans for single-dose COVID-19 vaccine Sputnik Light and also expects to “build on” the Russian partner’s trial in adolescents of the two-dose Sputnik V. The company also pilots a partnered first-of-its-kind cashless digital health offering.

Commercial Coronavirus COVID-19

Pfizer On Boosters, Kids And Prospects For A Long-Term COVID-19 Business

The company raised revenue guidance for its COVID-19 vaccine this year to a staggering $33bn from a prior estimate of $26bn.

Coronavirus COVID-19 Sales & Earnings
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

Latest From Policy & Regulation

Drug Pricing Measures Clear US Senate Judiciary Committee

They may have a good shot at passage given recent actions by President Biden and the Federal Trade Commission, and bipartisan interest in drug pricing. 

Pricing Debate Legislation

The Wait For Inspections: Biocon Seeks FDA Stance On Mutual Recognition Agreement Route

Biocon is awaiting a scheduled FDA pre-approval inspection for insulin aspart at its facility in Malaysia, amid concerns that the surge in COVID-19 cases in the Southeast Asian nation may cloud timelines. The Indian firm is also pursuing a mutual recognition agreement route with the agency for a generic product approval.

Biosimilars Regulation

Price Negotiation In Part D: Big Savings On Revlimid, Ibrance, Xtandi Projected in CAP Analysis

As Democrats in the US Congress work to move legislation empowering the Health and Human Services Department to negotiate drug prices directly with manufacturers, the Center For American Progress releases an analysis on which drugs would be targeted by House bill HR 3 and how much prices could be reduced.

Pricing Debate Legislation
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Latest From Research & Development

Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers

Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.

Clinical Trials Commercial

AGTC Moves Past Biogen With Ophthalmic Gene Therapy

AGTC hopes to gain the first approval in X-linked retinitis pigmentosa for its gene therapy AGTC-501, now in a Phase II/III study. It also is advancing development in achromatopsia, another unmet medical need.

Gene Therapy Rare Diseases

AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio

Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.

Deals Research and Development Strategies
See All
UsernamePublicRestriction

Register